Arcus Biosciences Inc at Citi BioPharma Conference Transcript
Let's start. So welcome back, everyone, to the panel track. I'm Yigal Nochomovitz, I'm one of the biotech analysts at Citi. So this is the immuno-oncology panel. I think this is the first time I've done an IO panel recently. So welcome everyone. We have the CEO of Arcus, Terry Rosen, welcome Terry; Mark Lanasa, the CMO of Solid Tumors at BeiGene, welcome; and Theresa Lavallee, the Chief Development Officer at Coherus, welcome, Theresa.
We just recently launched coverage on BeiGene and Coherus. And of course, Terry and Arcus, we've spent many years. So for those less familiar, why don't we just kind of run down the line and just -- I know there's a lot to talk about, but just give a very high-level 2-minute elevator pitch on the pipeline and just what are the key focus with -- I was trying to emphasize the IO angle, given that's the topic of the day. So okay, Mark.
Happy to be here today. So BeiGene, we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |